Anti-MDA-5 Antibody-positive Dermatomyositis after Allogeneic Bone Marrow Transplantation for Acute Transformation of Chronic Myelogenous Leukemia

Intern Med. 2023 Apr 1;62(7):1081-1087. doi: 10.2169/internalmedicine.9529-22. Epub 2022 Sep 6.

Abstract

Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody-positive dermatomyositis is a disease with a poor prognosis associated with rapid progressive interstitial pneumonia. Autoimmune diseases have occasionally been reported to occur after hematopoietic stem cell transplantation (HSCT). We experienced a case of anti-MDA-5 antibody-positive dermatomyositis after HSCT. In this case, a sufficient dose of cyclophosphamide could not be administered due to an impaired bone marrow function. We discuss the complications of autoimmune diseases after HSCT.

Keywords: MDA-5 antibody-positive dermatomyositis; hematopoietic stem cell transplantation.

Publication types

  • Case Reports

MeSH terms

  • Autoimmune Diseases*
  • Bone Marrow Transplantation / adverse effects
  • Chronic Disease
  • Dermatomyositis* / complications
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy

Substances

  • IFIH1 protein, human